PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors - PubMed (original) (raw)

doi: 10.1038/s43018-024-00756-7. Epub 2024 Apr 18.

Rahulsimham Vegesna # 3, Sumit Mukherjee 3, Ashwin V Kammula 3 4, Saugato Rahman Dhruba 3, Wei Wu 5, D Lucas Kerr 5, Nishanth Ulhas Nair 3, Matthew G Jones 6 7 8 9, Nir Yosef 6 7, Oleg V Stroganov 10, Ivan Grishagin 10 11, Kenneth D Aldape 12, Collin M Blakely 5 13, Peng Jiang 3, Craig J Thomas 11 14, Cyril H Benes 15, Trever G Bivona 5 13 16 17, Alejandro A Schäffer 3, Eytan Ruppin 18

Affiliations

• PMID: 38637658
• DOI: 10.1038/s43018-024-00756-7

PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors

Sanju Sinha et al. Nat Cancer. 2024 Jun.

Abstract

Tailoring optimal treatment for individual cancer patients remains a significant challenge. To address this issue, we developed PERCEPTION (PERsonalized Single-Cell Expression-Based Planning for Treatments In ONcology), a precision oncology computational pipeline. Our approach uses publicly available matched bulk and single-cell (sc) expression profiles from large-scale cell-line drug screens. These profiles help build treatment response models based on patients' sc-tumor transcriptomics. PERCEPTION demonstrates success in predicting responses to targeted therapies in cultured and patient-tumor-derived primary cells, as well as in two clinical trials for multiple myeloma and breast cancer. It also captures the resistance development in patients with lung cancer treated with tyrosine kinase inhibitors. PERCEPTION outperforms published state-of-the-art sc-based and bulk-based predictors in all clinical cohorts. PERCEPTION is accessible at https://github.com/ruppinlab/PERCEPTION . Our work, showcasing patient stratification using sc-expression profiles of their tumors, will encourage the adoption of sc-omics profiling in clinical settings, enhancing precision oncology tools based on sc-omics.

© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

PubMed Disclaimer

Similar articles

• Network-Based Matching of Patients and Targeted Therapies for Precision Oncology.
  Liu Q, Ha MJ, Bhattacharyya R, Garmire L, Baladandayuthapani V. Liu Q, et al. Pac Symp Biocomput. 2020;25:623-634. Pac Symp Biocomput. 2020. PMID: 31797633 Free PMC article.
• Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures.
  Suphavilai C, Chia S, Sharma A, Tu L, Da Silva RP, Mongia A, DasGupta R, Nagarajan N. Suphavilai C, et al. Genome Med. 2021 Dec 16;13(1):189. doi: 10.1186/s13073-021-01000-y. Genome Med. 2021. PMID: 34915921 Free PMC article.
• DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration.
  Wang Y, Yang Y, Chen S, Wang J. Wang Y, et al. Brief Bioinform. 2021 Sep 2;22(5):bbab048. doi: 10.1093/bib/bbab048. Brief Bioinform. 2021. PMID: 33822890
• Single-cell RNA sequencing and bioinformatics as tools to decipher cancer heterogenicity and mechanisms of drug resistance.
  Rosati D, Giordano A. Rosati D, et al. Biochem Pharmacol. 2022 Jan;195:114811. doi: 10.1016/j.bcp.2021.114811. Epub 2021 Oct 18. Biochem Pharmacol. 2022. PMID: 34673017 Review.
• New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
  Gerhards NM, Rottenberg S. Gerhards NM, et al. Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12. Drug Resist Updat. 2018. PMID: 29499836 Free PMC article. Review.

Cited by

• Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions.
  Pham TD, Teh MT, Chatzopoulou D, Holmes S, Coulthard P. Pham TD, et al. Curr Oncol. 2024 Sep 6;31(9):5255-5290. doi: 10.3390/curroncol31090389. Curr Oncol. 2024. PMID: 39330017 Free PMC article. Review.
• Bibliometric analysis of artificial intelligence in healthcare research: Trends and future directions.
  Senthil R, Anand T, Somala CS, Saravanan KM. Senthil R, et al. Future Healthc J. 2024 Sep 3;11(3):100182. doi: 10.1016/j.fhj.2024.100182. eCollection 2024 Sep. Future Healthc J. 2024. PMID: 39310219 Free PMC article.
• Star wars against leukemia: attacking the clones.
  Toma MM, Skorski T. Toma MM, et al. Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02369-6. Online ahead of print. Leukemia. 2024. PMID: 39223295 Review.
• Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood.
  Cao Y, Chang T, Schischlik F, Wang K, Sinha S, Hannenhalli S, Jiang P, Ruppin E. Cao Y, et al. Cancer Res Commun. 2024 Sep 1;4(9):2335-2348. doi: 10.1158/2767-9764.CRC-24-0092. Cancer Res Commun. 2024. PMID: 39113621 Free PMC article.

References

1. 1. Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020). - PubMed - PMC - DOI
2. 1. Huang, K., Xiao, C., Glass, L. M. & Critchlow, C. M. Machine learning applications for therapeutic tasks with genomics data. Patterns 2, 100328 (2021). - PubMed - PMC - DOI
3. 1. Bhinder, B., Gilvary, C., Madhukar, N. S. & Elemento, O. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 11, 900–915 (2021). - PubMed - PMC - DOI
4. 1. Singla, N. & Singla, S. Harnessing big data with machine learning in precision oncology. Kidney Cancer J. 18, 83–84 (2020). - PubMed - PMC
5. 1. Senft, D., Leiserson, M. D. M., Ruppin, E. & Ronai, Z. Precision oncology: the road ahead. Trends Mol. Med. 23, 874–898 (2017). - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group